Given the low-mild expression of EGFR reported in different osteosarcoma cell lines, including Saos-2, the clinical EGFR inhibitor gefitinib has been previously evaluated in vitro and found to have a moderate inhibitory effect on cell proliferation [31]. Here, EGFR is linked to osteosarcoma.